SAN DIEGO — Two monoclonal antibodies are now available in the U.S. as disease-modifying therapies for early Alzheimer’s disease, but there are concerns about the drugs that physicians must be aware of before prescribing them, an expert said.
Amyloid has been the focus of Alzheimer’s disease treatment strategies for decades, Zaldy S. Tan, MD, MPH, FACP, Carmen & Louis Warschaw Endowed Professor of Neurology & Medicine and director of the Bernard & Maxine Lynn Family Memory & Aging Program at Cedars Sinai Medical Center/David Geffen School of Medicine at the